A Prospective, Multicenter, Phase 2 Study of Imatinib Mesylate in Korean Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumor
Authors:
- Won Ki KangWKWon Ki Kang
- Yung-Jue BangYBYung-Jue Bang
- Kyung Hee LeeKLKyung Hee Lee
- Dong Bok ShinDSDong Bok Shin
- Baek-Yeol RyooBRBaek-Yeol Ryoo
- Jae Kyung RohJRJae Kyung Roh
- Jin-Hyoung KangJKJin-Hyoung Kang
- Hyoungnam LeeHLHyoungnam Lee
- Tae Won KimTKTae Won Kim
- Heung Moon ChangHCHeung Moon Chang
- Joon Oh ParkJPJoon Oh Park
- 23 March 2009
- journal article
- research article
- Published by S. Karger AG in Oncology
- Vol. 76 (5) , 326-332
Abstract
Objectives: This prospective, multicenter, phase 2 study evaluated the efficacy and safety of imatinib mesylate and assessed KIT and PDGFRA gene mutation status in Korean patients with gastrointestinal stromal tumors (GISTs). Methods: Forty-seven patients with pathologically proven KIT-positive metastatic or unresectable GISTs were accrued from eight institutions in Korea. Imatinib was administered orally at 400 mg once daily. In case of disease progression, the dose was escalated to 600 mg once daily, then 400 mg twice daily. KIT and PDGFRA mutations were analyzed in 29 of the 47 patients. Results: Imatinib produced partial responses in 30 patients (63.8%; 95% confidence interval, 50.1–77.6%) and stable disease in 13 patients (27.7%). The median time to response was 2.6 months (range, 1.0–6.2 months). With a median follow-up of 62 months (range, 32–67 months), 4-year progression-free survival and overall survival rates were 50 and 65%, respectively. The most common adverse events were anemia, neutropenia, edema, and skin rash (predominantly of grade 1–2). There were no treatment-related deaths. In the subset evaluated for mutational status, 24 patients (82.8%) had KIT exon 11 mutations and 1 (3.4%) had a KIT exon 9 mutation. Conclusions: Imatinib is effective and safe in Korean patients with metastatic or unresectable GIST.Keywords
This publication has 10 references indexed in Scilit:
- Dealing with Uncertainty in a Time of PlentyNew England Journal of Medicine, 2011
- Surrogate Decision-Makers' Perspectives on Discussing Prognosis in the Face of UncertaintyAmerican Journal of Respiratory and Critical Care Medicine, 2009
- United States Renal Data System 2007 Annual Data Report AbstractAmerican Journal of Kidney Diseases, 2008
- Hope and advance care planning in patients with end stage renal disease: qualitative interview studyBMJ, 2006
- Communicating prognosis in the dialysis consent process: A patient-centered, guideline-supported approachAdvances in Chronic Kidney Disease, 2005
- Theorizing About Causes at the Individual Level While Estimating Effects at the Population LevelEpidemiology, 2005
- Doctors expressions of uncertainty and patient confidencePatient Education and Counseling, 2002
- Evidence-Based Medicine, Clinical Uncertainty, and Learning to DoctorJournal of Health and Social Behavior, 2001
- Prognostic Disclosure to Patients with Cancer near the End of LifeAnnals of Internal Medicine, 2001
- Physician expressions of uncertainty during patient encountersPatient Education and Counseling, 2000